11:34 AM EST, 11/12/2025 (MT Newswires) -- Profound Medical ( PROF ) announced Wednesday an exclusive agreement with Getz Healthcare to distribute its TULSA-PRO system in Australia and New Zealand, extending the global reach of its AI-driven, MRI-guided prostrate therapy technology.

The TULSA Procedure, powered by Profound's TULSA-PRO system, uses robotically controlled, MRI-guided ultrasound to precisely ablate prostate tissue without incisions, enabling personalized treatment while safeguarding nearby structures.

Profound said it plans to expand its direct sales network in North America while partnering with global distributors to drive international adoption of its TULSA-PRO technology.

Shares of Profound Medical ( PROF ) were down 2.8% in recent trading.

Price: 6.20, Change: -0.18, Percent Change: -2.75